Current filters:


Popular Filters

7885 to 7909 of 8753 results

Italy’s Menarini takes giant step into Asia-Pacific, with acquisition of Invida


Italy’s leading independent drugmaker Menarini says it has acquired the Singapore-based Invida Group,…

Asia-PacificInvidaMenariniMergers & AcquisitionsPharmaceutical

New legislative amendments may result in huge losses for global pharma producers in Russia


Sergei Lisovsky, a well-known Russian senator and public figure, has put forward an initiative to make…


Bayer plans further capital spending of 1.8 billion euros in Asia


German pharma, crop and material sciences group Bayer (BAY: DE) this morning disclosed plans to further…

Asia-PacificBayerFinancialMarkets & MarketingPharmaceutical

Mixed results for AstraZeneca in study comparing Crestor with Lipitor


Anglo-Swedish drug major AstraZeneca (LSE: AZN) presented mixed results from a study comparing its cholesterol…


Galenica acquires Spanish JV Vifor Uriach and Grupo Uriach's primary care business


Swiss drugmaker Galenica (SIX: GALN) has acquired all the outstanding shares of Vifor Uriach Pharma SL,…

GalenicaMergers & AcquisitionsPharmaceuticalUriach

Sinclair IS Pharma divests Mysoline to Lab SERB for £11 million


UK specialty drugmaker Sinclair IS Pharma (AIM: SPH.L) says it has disposed of the epilepsy drug Mysoline…

Laboratoires SERBMergers & AcquisitionsMysolineNeurologicalPharmaceuticalSinclair IS Pharma

Increase in US drug recalls and warning caused by manufacturing errors and regulatory non-compliance issues, says GBI


The numbers of warning letters and drug recalls issued by and reported to the US Food and Drug Administration…

BiotechnologyNorth AmericaPharmaceuticalRegulation

Executive appointments at Merck KGaA and Pharmalink


Germany’s Merck KGaA (MRK: DE) has announced that Joachim Christ will join the company on January…

ManagementMerck KGaAPharmaceuticalPharmaLink

Genzyme’s MS drug Lemtrada shows significant efficacy versus Rebif


US biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) says that the Phase…


Japanese drug re-pricing issues raised by former Health Minister over TPP


Japan’s former Health Minister, Yoichi Masuzoe, and current leader of the New Renaissance Party,…

Asia-PacificMarkets & MarketingPharmaceuticalPricing

Angiotech opts out of cardiovascular cell therapy program with Athersys


Regenerative medicines firm Athersys (Nasdaq: ATHX) says that Canada’s Angiotech Pharmaceuticals…

AngiotechAthersysBiotechnologyFinancialLicensingMergers & Acquisitions

Dyax and Sigma Tau unit pull EU filing on Kalbitor


USA-based Dyax Corp (Nasdaq: DYAX) says it reached agreement with Defiante Farmaceutica, a unit of privately-held…

Defiante FarmaceuticaDyax CorpEuropeKalbitorPharmaceuticalRare diseasesRegulationSigma Tau

APEC Summit endorses Principles for Industry Codes of Ethics for pharma


The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said yesterday…

Asia-PacificMarkets & MarketingPharmaceuticalRegulation

Kenya gets $345 million from Global Fund for HIV/AIDS fight


Over the next few weeks, Kenya will be signing a $345 million grant agreement with the Global Fund to…

Anti-viralsFinancialHealthcarePharmaceuticalRest of the World

Faes Farma licences bilastine´s marketing rights in Indonesia to Kalbe


Spanish drugmaker Faes Farma has signed a licence agreement for the commercialization of its antihistamine…

Asia-PacificbilastineFaes FarmaKalbe PharmaLicensingPharmaceuticalRespiratory and Pulmonary

Another FDA rejection for Alimera’s DME drug Iluvien


Shares of US ophthalmic drug develop Alimera Sciences (Nasdaq: ALIM) plunged nearly 73% to $2 on Friday,…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

Novartis’ alisporivir may become first interferon-free oral for hepatitis C G2/G3


The clear conclusion from a clinical trial of alisporivir (DEB025, from Swiss drug major Novartis [NOVN:…


7885 to 7909 of 8753 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top